Spring Bank spears $10.5m Series A round for Phase I selective HCV drug
This article was originally published in Scrip
Spring Bank Pharmaceuticals raised $10.5 million in a Series A funding round to take a new mechanism of action for the treatment of hepatitis C virus (HCV) into clinical development via its lead oral, small molecule drug candidate SB 9200.
You may also be interested in...
Private Company Edition: While venture capital invested in the industry dropped in 2019, the number of deals rose as investors funded more early-stage VC rounds. Money continues flowing to large deals as well, including $105m for ALX Oncology and $98m for CANbridge.
Public Company Edition: Five out of six drug developers and a CRO have seen their values spike immediately after going public this month. Also, Moderna floats a $500m offering, Revance proposes a $20m note sale, and Nestle invests another $200m in Aimmune.
Biohaven is still studying its glutamate modulator in three other indications, but its biggest near-term milestone will be approval of the oral CGRP inhibitor rimegepant for acute migraine.